Celltrion launches biologics CDMO business 14th June 2018
Celltrion has launched its Bio CDMO business in a bid to pursue open innovation for the development of new drugs. Its operations will focus on the outsourcing of biologic cell line development and production process, and the manufacture and outsourcing of non-clinical, clinical and commercialized material.
Celltrion’s CDMO business aims to collaborate and partner with research institutes and biotech firms, possessing a new drug candidate molecules, in order to commercialize the aforementioned new drug candidate molecules. Celltrion plans to support partnered firms by sharing itss accumulated biologics development expertise, and may, through consultation and discussion, provide development cost or license in the molecule(s).
Celltrion is initially focusing on specific therapeutic areas which have the greatest synergy with its portfolio, such as autoimmune diseases (rheumatoid arthritis, inflammatory bowel diseases etc), breast cancer, lymphoma, and cardiovascular diseases – and is planning to gradually expand its therapeutic areas of interest.